Kura Oncology, Inc.
General ticker "KURA" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $760.2M (TTM average)
Kura Oncology, Inc. follows the US Stock Market performance with the rate: 42.0%.
Estimated limits based on current volatility of 2.6%: low 10.66$, high 11.24$
Factors to consider:
- Total employees count: 260 (+35.4%) as of 2025
- Company does not operate outside North America (retrieved using AI)
- Top business risk factors: Operational and conduct risks, No prior sales, Transition risks, Supply chain disruptions, Regulatory and compliance
- Price in estimated range
- Earnings for 3 months up through Q1 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [7.31$, 17.64$]
- 2026-12-31 to 2027-12-31 estimated range: [6.59$, 15.98$]
Financial Metrics affecting the KURA estimates:
- Positive: with PPE of -3.3 at the end of fiscal year the price was neutral
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Positive: 19.19 < Shareholder equity ratio, % of 23.58 <= 42.57
- Positive: Inventory ratio change, % of -10.80 <= -0.75
- Negative: negative Net income
- Positive: Interest expense per share per price, % of 0.16 <= 0.74
- Negative: negative Industry operating cash flow (median)
Short-term KURA quotes
Long-term KURA plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $53.88MM | $67.48MM |
| Operating Expenses | $165.80MM | $247.08MM | $371.11MM |
| Operating Income | $-165.80MM | $-193.19MM | $-303.63MM |
| Non-Operating Income | $13.17MM | $21.23MM | $25.26MM |
| Interest Expense | $1.55MM | $1.62MM | $1.51MM |
| R&D Expense | $115.23MM | $169.97MM | $251.07MM |
| Income(Loss) | $-152.63MM | $-171.97MM | $-278.37MM |
| Taxes | $0.00MM | $2.02MM | $0.30MM |
| Net Income(Loss)* | $-152.63MM | $-173.98MM | $-278.67MM |
| Stockholders Equity | $397.27MM | $413.64MM | $174.13MM |
| Inventory | $0.00MM | $0.00MM | $0.41MM |
| Assets | $448.94MM | $760.16MM | $738.36MM |
| Operating Cash Flow | $-124.82MM | $134.32MM | $-64.06MM |
| Capital expenditure | $0.17MM | $0.47MM | $6.64MM |
| Investing Cash Flow | $15.56MM | $-101.59MM | $-13.10MM |
| Financing Cash Flow | $94.78MM | $154.42MM | $1.79MM |
| Earnings Per Share** | $-2.08 | $-2.02 | $-3.18 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.